108 Results for "

CDK4/6

" in MedChemExpress (MCE) Product Catalog:
Products (108)

108 Results for "CDK4/6" in MCE Product Catalog:

  • Categories Recommended:
    More
Cat. No.: HY-126534S
Purity:  98.47%
Synonyms: LSN3106729-d8
Abemaciclib metabolite M18-d8 is the deuterium labeled Abemaciclib metabolite M18. Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .
loading...
    loading...
Cat. No.: HY-183771
CAS No.: 3110098-09-1
CDK4/6-IN-28 is a potent, orally active, and selective CDK4/6 inhibitor IC50 values of 14.02 and 10.03 nM, respectively. CDK4/6-IN-28 inhibits breast cancer cell colony formation, migration, and proliferation. CDK4/6-IN-28 induces G1-phase cell cycle arrest and apoptosis in breast cancer cells. CDK4/6-IN-28 exhibits tumor inhibitory activity in breast cancer xenograft mouse models. CDK4/6-IN-28 can be used for the research of breast cancer .
loading...
    loading...
Cat. No.: HY-184707
Target:  

CDK Apoptosis

Research Areas:  

Cancer

CDK4/6-IN-29 is an orally active and highly selective CDK4/6 inhibitor, with an IC50 of 3.17 nM against CDK4 and an IC50 of 4.91 nM against CDK6. CDK4/6-IN-29 induces apoptosis in non-small cell lung cancer cells, inhibits cancer cell migration, induces G1-phase cell cycle arrest, and exhibits anti-tumor efficacy in vivo. CDK4/6-IN-29 can be used for research related to non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-178350
Research Areas:  

Cancer

MFDCH016 is a potent HDAC1/6 (IC50 = 38/59 nM) and CDK4/6 (IC50 = 680/720 nM) inhibitor. MFDCH016 induces apoptosis and cell cycle arrest in G2/M and G0/G1 phases in MCF-7 cells. MFDCH016 can modulate the HDAC-p21-CDK signaling pathway, increasing the levels of acetylated H3 and p21. MFDCH016 can be used for the study of breast cancer .
loading...
    loading...
Cat. No.: HY-178512
Target:  

PROTAC Linkers

Research Areas:  

Cancer

Piperazine-CO-C1-Azacyclohexane-C1-Piperazine is a PROTAC linker can be used in the synthesis of PROTACs, such as PROTAC CDK4/6/9 degrader 1 (HY-178452) .
loading...
    loading...
Cat. No.: HY-112280A
CAS No.: 2567494-39-5
Purity:  99.37%
Target:  

CDK

Research Areas:  

Cancer

Crozbaciclib fumarate is a CDK4/6 inhibitor with IC50s of 3 and 1 nM, respectively.
loading...
    loading...
Cat. No.: HY-124398
CAS No.: 591242-70-5
Target:  

PAK

Research Areas:  

Cancer

GL-1196 is an inhibitor of PAK4. GL-1196 can suppress the proliferation and invasion of gastric cancer cells. GL-1196 inhibits PAK4-mediated signaling pathways. GL-1196 can hinder the proliferation of human gastric cancer cells through suppressing PAK4/c-Src/EGFR/CyclinD1 and CDK4/6. GL-1196 can reduce filamentous pseudopodia formation and induce filamentous pseudopodia formation and promote cell elongation in SGC7901 and BGC823 cells. GL-1196 can be studied in anti-cancer research .
loading...
    loading...
Cat. No.: HY-179151
Research Areas:  

Cancer

CDK4/6-IN-26 is a carbamate derivative that targets CDK4/CDK6. CDK4/6-IN-26 reduces CDK4/CDK6 levels, resulting in cell cycle arrest in the G0/G1 phase and in the S phase. CDK4/6-IN-26 exhibits high potency against SW480 cells (IC50 = 6.3 μM). CDK4/6-IN-26 affects ROS levels by increasing the expression of SOD2/MnSOD. CDK4/6-IN-26 establishes several interactions with the amino acids of the CDK6 active site. CDK4/6-IN-26 can be used for the research of colorectal cancer .
loading...
    loading...
Cat. No.: HY-101467AR
CAS No.: 1977495-97-8
Synonyms: G1T28 hydrochloride (Standard)
Target:  

Reference Standards CDK

Research Areas:  

Cancer

Trilaciclib (hydrochloride) (Standard) is the analytical standard of Trilaciclib (hydrochloride). This product is intended for research and analytical applications. Trilaciclib hydrochloride (G1T28 hydrochloride) is a CDK4/6 inhibitor with IC50s of 1 nM and 4 nM for CDK4 and CDK6, respectively .
loading...
    loading...
Cat. No.: HY-189130
CAS No.: 2699091-14-8
Target:  

CDK c-Myc

Research Areas:  

Cancer

CDK4/6-IN-30 is a selective, orally active CDK4 and CDK6 inhibitor with IC50 values of 10 nM and 16 nM, respectively. CDK4/6-IN-30 induces cell cycle arrest at G1 phase, inhibits RB phosphorylation, and decreases c-MYC and Cyclin D1 levels. CDK4/6-IN-30 exhibits anticancer activity against breast cancer. CDK4/6-IN-30 can be used for research on breast cancer .
loading...
    loading...
Cat. No.: HY-161847
CAS No.: 3030492-40-8
Target:  

Ser/Thr Protease

Research Areas:  

Cancer

HZ1 is an orally active first-in-class cyclin-dependent kinase like 3 (CDKL3)-specific inhibitor. HZ1 shows a strong tumor-suppressing effect, and has the potential to overcome the resistance of CDK4/6 inhibitor .
loading...
    loading...
Cat. No.: HY-162985
Target:  

CDK

Research Areas:  

Cancer

JHD205 is a CDK4/6 inhibitor that induces apoptosis and DNA damage. JHD205 inhibits DNA repair by upregulating Caspase3 and p-H2AX. JHD205 has superior potency to Abemaciclib (HY-16297A) in a xenograft chick embryo breast cancer model. .
loading...
    loading...
Cat. No.: HY-183571
CAS No.: 1934254-35-9
Target:  

CDK

Research Areas:  

Others

JD128 (Compound 22) is a CDK4/6 inhibitor .
loading...
    loading...
Cat. No.: HY-178515
Research Areas:  

Cancer

Thalidomide-piperazine-CO-C-azacyclohexane-C1-piperazine is a synthesized E3 ligase ligand-linker conjugate. Thalidomide-piperazine-CO-C-azacyclohexane-C1-piperazine can be used for synthesizing PROTAC CDK4/6/9 degrader 1 (HY-178452) .
loading...
    loading...
Cat. No.: HY-175638
Research Areas:  

Cancer

Carbonic anhydrase-IN-35 is a selective carbonic anhydrase (CA) inhibitor. Carbonic anhydrase-IN-35 potently inhibits tumor-associated hCA IX (Ki = 0.6 nM) and hCA XII (Ki = 2.2 nM). Carbonic anhydrase-IN-35 induces apoptosis in MCF-7 cells by elevating Bax, reducing Bcl-2, and downregulating CDK4/6. Carbonic anhydrase-IN-35 exhibits potent cytotoxicity against MCF-7 (IC50 = 0.3975 μM normoxic/0.6575 μM hypoxic), MCF-7-ADR (IC50> = 0.3975 μM normoxic/4.488 μM hypoxic), MDA-MB-231, and 4T1 breast cancer cells. Carbonic anhydrase-IN-35 can be used for the study of breast cancer .
loading...
    loading...
Cat. No.: HY-178517
Target:  

Ligands for E3 Ligase

Research Areas:  

Cancer

Thalidomide-C1-O-CO-C11 is a ligand for E3 ubiquitin ligase. Thalidomide-C1-O-CO-C11 can be connected to Aurora-A ligand 1 (HY-168440) by a linker (HY-178512) to form PROTAC CDK4/6/9 degrader 2 (HY-178516) .
loading...
    loading...
Cat. No.: HY-125101A
CAS No.: 1257792-42-9
Rafutrombopag (Hetrombopag) diolamine is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag diolamine can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag diolamine specifically stimulates proliferation and differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag diolamine effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag diolamine protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag diolamine can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .
loading...
    loading...
Cat. No.: HY-180574
CAS No.: 2619847-12-8
Target:  

DYRK

Research Areas:  

Cancer

TSL2109 is an orally active and selective DYRK2 and CDK4/6 inhibitor with an IC50 value of 22 nM for DYRK2. TSL2109 exhibits high kinase selectivity over 93%. TSL2109 arrests cell cycle and induces apoptosis in virto. TSL2109 effectively overcomes Enzalutamide (HY-70002) resistance by suppressing tumor growth in vivo and virto. TSL2109 also shows CDK4/6 inhibitor resistance.TSL2109 demonstrates safety profile. TSL2109 can be used for prostate cancer research and breast cancer [1][2].
loading...
    loading...
Cat. No.: HY-101467R
CAS No.: 1374743-00-6
Synonyms: G1T28 (Standard)
Target:  

CDK Reference Standards

Research Areas:  

Cancer

Trilaciclib (Standard) is the analytical standard of Trilaciclib (HY-101467). This product is intended for research and analytical applications. Trilaciclib (G1T28) is an orally active CDK4/6 inhibitor with IC50 values of 1 nM and 4 nM for CDK4 and CDK6, respectively. . Trilaciclib can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy .
loading...
    loading...
Cat. No.: HY-184649
CAS No.: 2922859-30-9
Target:  

CDK

Research Areas:  

Cancer

CDK2-IN-60 is an orally active, ATP-competitive selective CDK2 inhibitor with a Ki of 77 pM. CDK2-IN-60 has high selectivity for both CDK4 and CDK1. CDK2-IN-60 blocks G1/S cell cycle progression to suppress proliferation of CCNE1-amplified tumor cells. CDK2-IN-60 serves as a lead chemical probe for investigating CCNE1-amplified cancers and CDK4/6 inhibitor-resistant HR-positive breast cancer .
loading...
    loading...